Endostatin
Also known as: COL18A1 C-terminal fragment, Collagen XVIII fragment, Endostar, Endostatin, rh-Endostatin, YH-16
Source Endostatin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Endostatin is a 20‑kDa C‑terminal fragment of collagen XVIII that acts as a broad‑spectrum inhibitor of angiogenesis and has been investigated for anti‑cancer therapy.
Mechanism of Action
Inhibits endothelial cell proliferation, migration, and tube formation; binds integrins and VEGF receptors, induces endothelial apoptosis, and suppresses matrix metalloproteinase activity.
Routes of Administration
Goals & Uses
- Ocular neovascularization (wet AMD)OphthalmologyLow
- Cancer therapyOncologyModerate
- Colorectal cancer treatmentOncologyLow
- Non-small cell lung cancer treatmentOncologyModerate
- Breast cancer treatmentOncologyLow
- Anti‑angiogenic researchResearchHigh
- Anti-tumor angiogenesis inhibitionOncologyModerate
Contraindications
- Active hemorrhage or coagulopathyHematologicModerate
- Severe hepatic impairmentOrganModerateLiver function concerns
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Hypersensitivity to endostatin or excipientsAllergy / ImmunologyHigh
Adverse Effects
- Nausea / VomitingGastrointestinalUncommon
- HypertensionCardiovascularUncommonHigh blood pressure
- Injection site reactionsLocalCommon
- HypotensionCardiovascularUnknownLow blood pressure
- FatigueGeneralUnknownLow energy or tiredness
- Elevated liver enzymes (transaminases)HepaticUncommon
- ThromboembolismCardiovascularRare
Drug Interactions
- Other anti-angiogenic agents (bevacizumab, sunitinib)Moderate
- Anticoagulants (warfarin, heparin)Moderate
- Vinorelbine / Cisplatin (NP regimen)Moderate
Population Constraints
- Pediatric patientsAgeRelative
- Breastfeeding womenReproductiveRelative
- Patients with active bleeding disordersHematologicRelative
- Pregnant womenReproductiveAbsolute
Regulatory Status
- European UnionUnapprovedNo EMA marketing authorization.
- United StatesUnapprovedInvestigational only; no FDA approval.
- United KingdomUnapprovedNot licensed by MHRA.
Not approved for clinical use in any major jurisdiction; investigated in pre‑clinical and early‑phase clinical trials.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Endostatin?
Endostatin is a 20‑kDa C‑terminal fragment of collagen XVIII that acts as a broad‑spectrum inhibitor of angiogenesis and has been investigated for anti‑cancer therapy.
What is Endostatin used for?
Endostatin is educationally associated with: Ocular neovascularization (wet AMD), Cancer therapy, Colorectal cancer treatment, Non-small cell lung cancer treatment, Breast cancer treatment, Anti‑angiogenic research, Anti-tumor angiogenesis inhibition. Educational only — not medical advice.
How is Endostatin administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Endostatin?
Reported adverse effects include: Nausea / Vomiting, Hypertension, Injection site reactions, Hypotension, Fatigue, Elevated liver enzymes (transaminases), Thromboembolism. This list is not exhaustive — consult a qualified clinician.
Who should avoid Endostatin?
Recorded contraindications: Active hemorrhage or coagulopathy, Severe hepatic impairment, Pregnancy, Hypersensitivity to endostatin or excipients. Consult a qualified clinician before use.